co-supplementation of flaxseed and hesperidin improves atherogenic dyslipidemia in people with excess weight: a randomized controlled clinical trial

Background and objectives: the increase in the risk of cardiovascular diseases, one of the leading causes of death in the world, due to obesity is significant. this study was carried out suggesting palliative effects of the combination of brown flaxseed and hesperidin on atherogenic dyslipidemia in obese people.materials and methods: in this randomized controlled study, 44 obese adults were randomly assigned to lifestyle modification (control group) or receiving combined brown flaxseed (30 g) and hesperidin (2 × 500 mg capsules) (intervention group) for 12 w. atherogenic indices, anthropometric parameters and dietary intakes were recorded. the trial was registered in clinicaltrial.gov. with reg. no. nct03737422.results: after 12 w of intervention, body mass index decreased significantly in groups; however, decrease of body mass index in intervention group was significantly higher than that in control group (p = 0.034). comparing changes of atherogenic indices between the two groups indicated a significant difference in triglyceride glucose index, atherogenic index of plasma and cholesterol index between the two groups. after adjusting results for condetecteders, including baseline value of the outcome and mean changes in body mass index, waist circumference and energy intake, differences became significant for castelli risk index-ii and lipoprotein combine index.conclusions: the current results have shown that intake of a combination of flaxseed and hesperidin with lifestyle modification effectively improves atherogenic dyslipidemia.